FDA Approves First Targeted Treatment of Polyneuropathy in Rare Disease


Officials with the FDA have approved the first targeted treatment for adult patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, a rare and often fatal disease.

Officials with the FDA have approved the first targeted treatment for adult patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR), a rare and often fatal disease, according to a press release.

Affecting approximately 50,000 people worldwide, hATTR can be debilitating—interfering with normal functioning through the buildup of abnormal deposits of protein fibers called amyloid in the body’s organ and tissues. As a result, patients may experience loss of sensation, pain, or immobility in the arms, legs, hands, and feet. These deposits can also affect the functioning of the heart, kidneys, eyes, and gastrointestinal tract.

The drug, patisiran (Onpattro, Alnylam Pharmaceuticals) infusion, is the first to be approved of a new class called small interfering ribonucleic acid (siRNA) treatment. This new drug class works by silencing a portion of RNA involved in causing the disease, according to the FDA. Specifically, treatment is designed to interfere with RNA production of an abnormal form of the protein transthyretin (TTR) to reduce the accumulation of amyloid deposits in peripheral nerves.

The approval is based efficacy data from a clinical trial involving 225 patients, 148 of whom were randomly assigned to receive patisiran infusion once every 3 weeks for 18 months, and 77 of whom were randomly assigned to receive a placebo infusion at the same frequency. According to the data, patisiran-treated patients had better outcomes on measures of polyneuropathy, including muscle strength, sensation, reflexes, and autonomic symptoms compared with patients who received the placebo. Patients who received patisiran also scored better on assessments of walking, nutritional status, and the ability to perform activities of daily living.

“There has been a long-standing need for a treatment for hereditary transthyretin-mediated amyloidosis polyneuropathy,” Billy Dunn, MD, director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research, said in a statement. “This unique targeted therapy offers these patients an innovative treatment for their symptoms that directly affects the underlying basis of this disease.”

Common adverse effects reported by patients treated with patisiran are infusion-related reactions including flushing, back pain, nausea, abdominal pain, dyspnea, and headache. Patients may also experience vision problems and decreased serum vitamin A levels, according to the FDA.

This article was originally published at SpecialtyPharmacyTimes.com.


FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease [news release]. FDA’s website. http://www.pharmacytimes.com/link/201. Accessed August 10, 2018.

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii | stock.adobe.com
Pharmacy Interior | Image Credit: Tyler Olson - stock.adobe.com
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi - stock.adobe.com
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen | stock.adobe.com
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/peopleimages.com | stock.adobe.com
Image credit: fidaolga - stock.adobe.com
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund | stock.adobe.com
Young male pharmacist giving prescription medications to senior female customer in a pharmacy | Image Credit: Zamrznuti tonovi - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.